10-K: SI-BONE, Inc. Reports FY2024 Results, Highlights Growth and Strategic Initiatives

Sentiment:

Annual Results 25 February 2025 4:10 PM

SI-BONE, Inc.'s 10-K filing summarizes the company's FY2024 performance, strategic initiatives, and associated risks.

Delay expectedFrom time to time, the company has experienced certain delays and may experience delays from its suppliers in the future.

Worse than expectedThe company has incurred significant operating losses since its inception in 2008, with net losses of $30.9 million in 2024, $43.3 million in 2023, and $61.3 million in 2022, and an accumulated deficit of $431.4 million as of December 31, 2024.

Summary

SI-BONE, Inc., a medical device company focused on musculoskeletal disorders of the sacropelvic anatomy, filed its annual report on Form 10-K for the fiscal year ended December 31, 2024.
The company has incurred significant operating losses since its inception in 2008, with net losses of $30.9 million in 2024, $43.3 million in 2023, and $61.3 million in 2022, and an accumulated deficit of $431.4 million as of December 31, 2024.
SI-BONE's revenue primarily comes from the sale of iFuse, iFuse-3D, iFuse TORQ, and iFuse Bedrock Granite implants, and related tools and instruments.
The company estimates its total addressable market in the United States exceeds $3.0 billion, targeting sacroiliac joint dysfunction, spinopelvic fixation, and pelvic fractures.
As of December 31, 2024, over 115,000 procedures have been performed using SI-BONE's products by over 4,300 physicians in the United States and 38 other countries since the introduction of iFuse in 2009.
In May 2023, SI-BONE received $83.7 million in net proceeds from a public offering of common stock.
The company is actively pursuing additional 510(k) clearances for new products and changes to the current indication for iFuse.
SI-BONE faces competition from larger medical device companies like Globus Medical, Inc. and Medtronic plc.
The company's current U.S. patents on the design of its first generation iFuse implant, including its triangular shape, expire in December 2025.
In October 2024, SI-BONE received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue increased and losses decreased, the company still faces significant risks and challenges, including competition, supply chain disruptions, and regulatory hurdles.

Positives

The company has a large addressable market.
SI-BONE's products are supported by substantial high-quality published evidence of safety, clinical effectiveness, durability, and economic utility.
The company has a dedicated direct salesforce focused on sacropelvic solutions.
SI-BONE has received exclusive reimbursement coverage in the United States by certain payors based upon its differentiated product and quality of its evidence as well as NTAP and TPT given the breakthrough designation of certain devices.
The company is actively pursuing additional 510(k) clearances for new products and changes to the current indication for iFuse.

Negatives

SI-BONE has incurred significant operating losses since inception and may continue to do so.
The company is highly dependent on revenue from a single family of products.
SI-BONE operates in a very competitive business environment.
The company is dependent on a limited number of third-party suppliers, some of them single-source.
The company's current U.S. patents on the design of its first generation iFuse implant, including its triangular shape, expire in December 2025.
In October 2024, SI-BONE received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.

Risks

The company may not be able to convince physicians that its products are attractive alternatives to competitors' products.
Uncertainty in the coverage and reimbursement environment may decrease demand for SI-BONE's products.
Pricing pressure from competitors, healthcare provider consolidation, and payor consolidation may impact the company's ability to sell its products at prices necessary to support its current business strategies.
Prolonged inflation and supply chain disruptions could result in delayed product launches, lost revenue, higher costs, and decreased profit margins.
If clinical experience with SI-BONE's products does not result in positive outcomes for patients, sales could be adversely impacted.
The company's business could suffer if it loses the services of key members of its senior management, key advisors, or personnel.
If use of SI-BONE's products results in adverse events, this may require them to be taken off the market, require them to include safety warnings, or otherwise limit their sales.
SI-BONE and its sales representatives must comply with U.S. federal and state fraud and abuse laws, including those relating to healthcare provider kickbacks and false claims for reimbursement, and other applicable federal and state healthcare laws, as well as equivalent foreign laws, and failure to comply could negatively affect the company's business.
If SI-BONE or its licensors fail to adequately protect or enforce its intellectual property rights or secure rights to patents of others, the value of its intellectual property rights would diminish and its ability to successfully commercialize its products may be impaired.

Future Outlook

The company anticipates that research and development expenses will continue to increase in the future and that more outpatient eligible procedures will be performed in ASCs and OBLs to control costs and expand patient access to medical procedures.

Industry Context

The medical device industry is highly competitive and subject to rapid change, with increasing pricing pressure and consolidation among healthcare providers and payors.

Comparison to Industry Standards

The document mentions competitors such as Globus Medical, Inc. and Medtronic plc, which are large, publicly traded companies with wide product offerings for spine and orthopedic surgery.
SI-BONE believes its implants are currently used in the majority of minimally invasive surgical fusions and/or fixation of the sacroiliac joint in the United States.
The company believes it has the most comprehensive set of solutions which are supported by clinical evidence including randomized controlled studies that demonstrate the safety, clinical effectiveness, durability, and economic utility.

Legal Proceedings

In October 2024, SI-BONE received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
The CID requests information and documents primarily relating to meals and consulting service payments provided to health-care professionals.

Related Party Transactions

On February 24, 2020, the Company entered into a joint development agreement (the Development Agreement) with SeaSpine Orthopedics Corporation (SeaSpine), which recently merged with Orthofix Medical, Inc. (Orthofix), to develop a next generation device for sacropelvic fixation.
Mr. Keith Valentine, who serves as the President, Chief Executive Officer and a member of the board of directors of SeaSpine, also serves as a member of the Company's Board of Directors since August 2015.
On October 4, 2023, Keith C. Valentine resigned as a member of the Board of Directors of Orthofix. As such, subsequent to October 4, 2023, SeaSpine is no longer a related party of the Company.

Stakeholder Impact

The company's performance and strategic initiatives impact shareholders, employees, customers (physicians and patients), suppliers, and creditors.
The company's ability to innovate, compete, and comply with regulations affects its long-term viability and value for stakeholders.

Next Steps

The company plans to pursue additional 510(k) clearances for new products and changes to the current indication for iFuse.
SI-BONE expects to publish main results from the SILVIA study (2-year follow-up) and follow-up results from the STACI study in 2025.
The company expects to publish six-month results from the PAULA study in late 2025.

Key Dates

Date	Description
March 2008	SI-BONE was incorporated.
2009	Launch of first generation iFuse.
November 2008	SI-BONE received 510(k) clearance to market its first generation iFuse implant from the FDA.
November 2010	SI-BONE obtained a CE Certificate of Conformity from its Notified Body (DEKRA) and affixed a CE mark to its iFuse Implant System.
2017	Launch of iFuse-3D.
April 2019	SI-BONE received clearance from the FDA to promote the use of its iFuse-3D implants for fusion of the sacroiliac joint in conjunction with multi-level spinal fusion procedures.
December 2019	SI-BONE CE marked and began marketing iFuse for the Bedrock technique in the European Union (EU).
March 2020	SI-BONE received FDA 510(k) clearance for an expanded indication for its triangular titanium iFuse implants to support its trauma initiative.
July 2020	SI-BONE began using the SI-BONE SImulator for surgery training.
February 2021	SI-BONE launched iFuse TORQ, a line of 3D-printed threaded implants.
May 26, 2021	The European Union no longer applies the Mutual Recognition Agreement between the EEA and Switzerland.
May 2022	SI-BONE launched its iFuse Bedrock Granite Implant System and received 510(k) clearance from the FDA for iFuse Bedrock Granite.
June 2022	SI-BONE received an additional 510(k) clearance from the FDA to extend the use of iFuse TORQ to include fragility fractures.
August 16, 2022	President Biden signed the Inflation Reduction Act of 2022 (IRA) into law.
August 2022	CMS issued a final decision for a NTAP of up to $9,828 for eligible cases using iFuse Bedrock Granite in the hospital inpatient setting.
September 2022	SI-BONE received 510(k) clearance from the FDA for use of iFuse TORQ using the Bedrock technique.
October 1, 2022	NTAP became effective for iFuse Bedrock Granite.
May 2023	SI-BONE received $83.7 million of net proceeds from the offering of common stock.
June 2023	SI-BONE received 510(k) clearance from the FDA for iFuse TORQ placement in the posterolateral or lateral oblique trajectory.
August 2024	SI-BONE received 510(k) clearance from the FDA for the iFuse TORQ TNT Implant System.
January 2024	SI-BONE received FDA clearance for a smaller diameter (9.5mm) iFuse Bedrock Granite implant with both an expanded indication that covers pediatric patients and an expanded application that includes use in the S1 trajectory.
January 1, 2024	The American Medical Association (AMA) adopted a separate Category 1 CPT code 27278 to describe minimally invasive sacroiliac fusion when performed using an intra-articular implant.
January 1, 2025	TPT for iFuse Bedrock Granite became effective.
October 2024	SI-BONE received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act.
December 31, 2024	Over 115,000 procedures have been performed using SI-BONE's products since 2009.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.